Pharmacists’ Role in Helping Patients Manage COPD | ASHP Midyear
Drug Topics
DECEMBER 12, 2024
Lourdes Cross, PharmD, BCACP, CDCES, discussed chronic obstructive pulmonary disease and how pharmacists are positioned to help patients exacerbations.
Thu.Dec 12, 2024
469 
STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more
STAT
DECEMBER 12, 2024
Top of the morning to you, and a fine one it is. Clear blue skies and chilly breezes are wafting across the Pharmalot campus, where the official mascots are snoozing after foraging for their breakfast. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is maple cinnamon French toast.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Pharmacists Play Key Role in Educating Patients About RSV Vaccine | ASHP Midyear
Drug Topics
DECEMBER 12, 2024
A conversation with Chelsea Keedy, PharmD, BCACP, clinical assistant professor at the University of Georgia.
STAT+: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds
STAT
DECEMBER 12, 2024
During 2023, drugmakers substantially raised prices on five widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $815 million last year, according to a new report. The drug for which spending increased the most due to a price increase was Biktarvy, which is prescribed to treat HIV and is a franchise product for Gilead Sciences.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Q&A: Pharmacist Discusses Unique Challenges in Psychiatric Population
Drug Topics
DECEMBER 12, 2024
Nina Vadiei, PharmD, BCPP, discusses some of the challenges she faces working with forensic patients who have been charged with a crime and have severe mental illness.
STAT+: AI versus AI: The emerging arms race over health insurance denials
STAT
DECEMBER 12, 2024
Like many Americans, Holden Karau said she was fed up with health insurance. The software engineer’s disillusionment began in 2019, when her insurer, UnitedHealthcare, balked at covering physical therapy after she was hit by a car and could not walk. She said the hassles piled on stress, forced her to pay more out of pocket, and delayed access to care she needed to recover from multiple broken bones.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
CDC finds no evidence of bird flu virus in California toddler
STAT
DECEMBER 12, 2024
Testing of samples taken from a child in California thought to have contracted H5N1 bird flu after drinking raw milk turned up no evidence of influenza viruses, the Centers for Disease Control and Prevention said Thursday. A test run on a sample from the child — who went to a Marin County emergency department last week with a fever and vomiting — had been positive there for flu A.
Gap in Biosimilar Knowledge Causes Barriers to Implementation | ASHP Midyear
Drug Topics
DECEMBER 12, 2024
Amanuel Kehasse, PharmD, PhD, explored reasons why patients and providers may be avoiding the implementation of biosimilar medications.
STAT+: Editas Medicine lays off 65% of staff and shelves lead gene-editing program
STAT
DECEMBER 12, 2024
Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus. The cuts come amid a prolonged financial downturn for the gene-editing field, as valuations have plummeted and layoffs have become widespread. Editas already laid off staff as part of a restructuring in 2023.
Is compounded semaglutide safe?
The Checkup by Singlecare
DECEMBER 12, 2024
Semaglutide has become a very popular drug thats in high demand in pharmacies everywhere and is currently also available from compounding pharmacies and online. But not all compounded semaglutide products are safe. In fact, the Food and Drug Administration (FDA) says consumers should exercise a lot of caution when considering using a compounded drug.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Opinion: What I’ve learned — the hard way — about AI in bio
STAT
DECEMBER 12, 2024
As we approach the end of 2024, First Opinion is publishing a series of essays on the state of AI in medicine and biopharma. There’s more to life than protein folding.
Tirzepatide Demonstrates Superiority for Weight Loss Compared With Semaglutide
Pharmacy Times
DECEMBER 12, 2024
The full results will be published in a peer-reviewed journal and presented at a medical meeting next year as the full results are evaluated.
STAT+: Arcellx won the battle of BCMA CAR-T therapies
STAT
DECEMBER 12, 2024
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of BCMA CAR-T therapies against Legend Biotech. Legend has downplayed the significance of the 12-17% rate of delayed neurotoxicity — Parkinsonian symptoms and cranial nerve palsies — report
Study: Dark Chocolate Consumption Lowers Risk of Type 2 Diabetes
Pharmacy Times
DECEMBER 12, 2024
Pharmacists play an essential role in educating patients about various health-related topics, including type 2 diabetes and nutrition.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Opinion: In a threat to patient trust, Texas hospitals must ask ‘Are you a U.S. citizen?’
STAT
DECEMBER 12, 2024
As a first-generation immigrant, much of my childhood was spent in a state of perpetual uncertainty. My family and I fixated on an ever-refreshing screen, patiently watching our status shift from “H-1B visa” to “green card” holder to “citizen” over 14 long years. Yet amid this endless cycle of anxiety, one place surprisingly gave me solace: the hospital.
Benralizumab Achieves Positive Outcomes in Eosinophilic Exacerbations in Asthma, COPD
Pharmacy Times
DECEMBER 12, 2024
Compared prednisolone alone, benralizumab with and without prednisolone resulted in fewer treatment failures and stronger VAS scores.
Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company
Pharmafile
DECEMBER 12, 2024
12 December 2024 London, UK, and Palo Alto, CA, US Deep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration to create a company focused on developing novel treatments for fibrosis. Widely recognised as an area of significant unmet need, Deep Science Ventures and General […] The post Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company appeared first on Pharmafile.
Belumosudil Commonly Used in Combination and After 3 or More Prior Lines of Therapy in Patients With cGVHD
Pharmacy Times
DECEMBER 12, 2024
Patients with chronic graft-versus-host disease (cGVHD) were most likely to receive belumosudil in the fourth line (33.7%) setting or the fifth through seventh line (33.1%).
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
When AI becomes a tool to fight insurance denials
STAT
DECEMBER 12, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Companies use AI to fight insurance denials People infrequently challenge health insurance denials even though appeals are often successful.
FDA Reports Serious Liver Injury in Patients Without Cirrhosis Using Obeticholic Acid to Treat PBC
Pharmacy Times
DECEMBER 12, 2024
This update follows May 2021 guidelines which recommended patients with primary biliary cholangitis (PBC) with advanced cirrhosis discontinue obeticholic acid.
The biotech news you need to read today
STAT
DECEMBER 12, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, let’s get straight into the news today.
ASHP Midyear: Pharmacists Play Crucial Role in Skin Care Recommendations
Pharmacy Times
DECEMBER 12, 2024
Pharmacists are crucial skin care experts and should counsel patients on the importance of adjunct therapies like moisturizers and sunscreen when using certain medications.
Nobel laureates ‘strongly urge’ Senate to oppose confirmation of RFK Jr
Pharmaceutical Technology
DECEMBER 12, 2024
In the letter, 77 Nobel Prize winners argue that appointing RFK as Secretary of HHS would put the US publics health in jeopardy.
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
PharmaVoice
DECEMBER 12, 2024
At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.
UK indefinitely bans puberty blockers for teenagers due to “unacceptable risk”
Pharmaceutical Technology
DECEMBER 12, 2024
Puberty blockers for people aged under 18 with gender dysphoria will be indefinitely banned by the UK Government.
Understanding Adrenal Fatigue
Compounding Pharmacy of America
DECEMBER 12, 2024
Discover the symptoms, causes, and natural treatments for adrenal fatigue. Learn how tools like the Adrenal Stress Test Kit and targeted supplements can restore balance and energy. The post Understanding Adrenal Fatigue appeared first on Compounding Pharmacy of America.
Sanofi’s combo vaccines gain FDA fast track designation
Pharmaceutical Technology
DECEMBER 12, 2024
Sanofi has announced that its two combination vaccine candidates have received fast track status from the US FDA.
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
Fierce Pharma
DECEMBER 12, 2024
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. | This week on The Top Line, we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and whats next for the GLP-1 drug class.
Flu vaccine strategy on the line as new US leaders anticipated to take charge
Pharmaceutical Technology
DECEMBER 12, 2024
Public health experts are anticipating a changing discourse following RFK Jrs appointment as head of HHS.
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
Fierce Pharma
DECEMBER 12, 2024
In the Institute for Clinical and Economic Reviews (ICERs) annual price-hike report, the U.S. | The U.S. watchdog is taking several pharma majors to task over what it says are "unsupported" price increases. But many of the companies have been quick to hit back against ICERs findings.
Is compounded semaglutide the same as Ozempic?
The Checkup by Singlecare
DECEMBER 12, 2024
Ozempic (semaglutide) is a brand-name, once-weekly injectable prescription medication thats used to help control blood sugar levels in adults with Type 2 diabetes , as well as to lower the risk of major adverse cardiovascular events (such as heart attack and stroke ) in adults with both Type 2 diabetes and heart disease. Ozempic is also sometimes prescribed off-label (for a non-FDA-approved use) as a weight loss drug.
After M&A rumors sparked stock volatility, Bausch + Lomb confirms it's exploring a sale
Fierce Pharma
DECEMBER 12, 2024
Twenty-one months into his second tenure as CEO of Bausch + Lomb, serial dealmaker Brent Saunders has so far come up empty in his latest attempt to sell the company. | Bausch + Lomb has issued a statement saying that its board had authorized management and its advisors to explore a potential sale, which is one of several options being explored to complete a full separation from its parent, Bausch Health Companies.
Noema Pharma raises $147 million to develop drugs for neurological conditions
Outsourcing Pharma
DECEMBER 12, 2024
Noema Pharma extends its series B funding to $147M, advancing phase 2 trials for CNS disorders like Tourette syndrome, menopause symptoms, and neuropathic pain.
Let's personalize your content